Suggestions for Escaping the Dark Ages for Pediatric Diffuse Intrinsic Pontine Glioma Treated with Radiotherapy: Analysis of Prognostic Factors from the National Multicenter Studyopen access
- Authors
- 김현주; 이주호; 김영경; 임도훈; 박신형; 안승도; 김인아; 임정호; 정재욱; 김주영; 김일한; 윤홍인; 서창옥
- Issue Date
- Jan-2023
- Publisher
- 대한암학회
- Keywords
- Diffuse intrinsic pontine glioma; Radiotherapy; Prognosis
- Citation
- Cancer Research and Treatment, v.55, no.1, pp.41 - 49
- Journal Title
- Cancer Research and Treatment
- Volume
- 55
- Number
- 1
- Start Page
- 41
- End Page
- 49
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/87972
- DOI
- 10.4143/crt.2021.1514
- ISSN
- 1598-2998
- Abstract
- PurposeThis multicenter retrospective study aimed to investigate clinical, radiologic, and treatment-related factors affecting survival in patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) treated with radiotherapy.Materials and MethodsPatients aged <30 years who underwent radiotherapy as an initial treatment for DIPG between 2000 and 2018 were included; patients who did not undergo magnetic resonance imaging at diagnosis and those with pathologically diagnosed grade I glioma were excluded. We examined medical records of 162 patients collected from 10 participating centers in Korea. The patients’ clinical, radiological, molecular, and histopathologic characteristics, and treatment responses were evaluated to identify the prognosticators for DIPG and estimate survival outcomes.ResultsThe median follow-up period was 10.8 months (interquartile range, 7.5 to 18.1). The 1- and 2-year overall survival (OS) rates were 53.5% and 19.0%, respectively, with a median OS of 13.1 months. Long-term survival rate (≥ 2 years) was 16.7%, and median OS was 43.6 months. Age (< 10 years), poor performance status, treatment before 2010, and post-radiotherapy necrosis were independently associated with poor OS in multivariate analysis. In patients with increased post-radiotherapy necrosis, the median OS estimates were 13.3 months and 11.4 months with and without bevacizumab, respectively (p=0.138).ConclusionTherapeutic strategy for DIPG has remained unchanged over time, and the associated prognosis remains poor. Our findings suggest that appropriate efforts are needed to reduce the occurrence of post-radiotherapy necrosis. Further well-designed clinical trials are recommended to improve the poor prognosis observed in DIPG patients.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.